Logo image of NVTA

INVITAE CORP (NVTA) Stock Fundamental Analysis

NYSE:NVTA - New York Stock Exchange, Inc. - US46185L1035 - Common Stock - Currency: USD

0.0891  -0.3 (-77.12%)

Fundamental Rating

2

Overall NVTA gets a fundamental rating of 2 out of 10. We evaluated NVTA against 108 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of NVTA have multiple concerns. NVTA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year NVTA has reported negative net income.
In the past year NVTA has reported a negative cash flow from operations.
NVTA had negative earnings in each of the past 5 years.
In the past 5 years NVTA always reported negative operating cash flow.
NVTA Yearly Net Income VS EBIT VS OCF VS FCFNVTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -1B -2B -3B

1.2 Ratios

NVTA's Return On Assets of -269.22% is on the low side compared to the rest of the industry. NVTA is outperformed by 96.49% of its industry peers.
NVTA's Return On Invested Capital of 381.98% is amongst the best of the industry. NVTA outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA -269.22%
ROE N/A
ROIC 381.98%
ROA(3y)-61.41%
ROA(5y)-52.18%
ROE(3y)-1031.52%
ROE(5y)-647.66%
ROIC(3y)N/A
ROIC(5y)N/A
NVTA Yearly ROA, ROE, ROICNVTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -1K -2K -3K

1.3 Margins

NVTA has a better Operating Margin (378.20%) than 100.00% of its industry peers.
NVTA has a Gross Margin of 27.14%. This is comparable to the rest of the industry: NVTA outperforms 51.75% of its industry peers.
In the last couple of years the Gross Margin of NVTA has declined.
Industry RankSector Rank
OM 378.2%
PM (TTM) N/A
GM 27.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.59%
GM growth 5Y-3.73%
NVTA Yearly Profit, Operating, Gross MarginsNVTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NVTA is creating value.
The number of shares outstanding for NVTA has been increased compared to 1 year ago.
The debt/assets ratio for NVTA is higher compared to a year ago.
NVTA Yearly Shares OutstandingNVTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
NVTA Yearly Total Debt VS Total AssetsNVTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of -3.51, we must say that NVTA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.51, NVTA is doing worse than 86.84% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.51
ROIC/WACC172.06
WACC2.22%
NVTA Yearly LT Debt VS Equity VS FCFNVTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 1B 2B

2.3 Liquidity

NVTA has a Current Ratio of 2.39. This indicates that NVTA is financially healthy and has no problem in meeting its short term obligations.
NVTA has a Current ratio of 2.39. This is in the better half of the industry: NVTA outperforms 79.82% of its industry peers.
NVTA has a Quick Ratio of 2.25. This indicates that NVTA is financially healthy and has no problem in meeting its short term obligations.
NVTA's Quick ratio of 2.25 is fine compared to the rest of the industry. NVTA outperforms 78.95% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.25
NVTA Yearly Current Assets VS Current LiabilitesNVTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

NVTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.74%, which is quite impressive.
The Revenue has decreased by -7.37% in the past year.
NVTA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 49.91% yearly.
EPS 1Y (TTM)58.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.19%
Revenue 1Y (TTM)-7.37%
Revenue growth 3Y33.54%
Revenue growth 5Y49.91%
Sales Q2Q%-9.21%

3.2 Future

The Earnings Per Share is expected to grow by 12.71% on average over the next years. This is quite good.
NVTA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.73% yearly.
EPS Next Y53.25%
EPS Next 2Y26.21%
EPS Next 3Y18.34%
EPS Next 5Y12.71%
Revenue Next Year-6.03%
Revenue Next 2Y0.81%
Revenue Next 3Y3.75%
Revenue Next 5Y3.73%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NVTA Yearly Revenue VS EstimatesNVTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
NVTA Yearly EPS VS EstimatesNVTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NVTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVTA Price Earnings VS Forward Price EarningsNVTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NVTA is valued cheaply inside the industry as 98.25% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.53
NVTA Per share dataNVTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

NVTA's earnings are expected to grow with 18.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.21%
EPS Next 3Y18.34%

More info and screens

0

5. Dividend

5.1 Amount

NVTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVITAE CORP

NYSE:NVTA (2/5/2024, 7:40:05 PM)

0.0891

-0.3 (-77.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-08 2023-11-08/amc
Earnings (Next)02-21 2024-02-21/amc
Inst Owners0.08%
Inst Owner Change-0.12%
Ins Owners3.24%
Ins Owner Change0%
Market Cap25.53M
Analysts46.15
Price Target0.72 (708.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.39%
Min EPS beat(2)19.77%
Max EPS beat(2)69%
EPS beat(4)4
Avg EPS beat(4)33.24%
Min EPS beat(4)7.42%
Max EPS beat(4)69%
EPS beat(8)6
Avg EPS beat(8)21.36%
EPS beat(12)6
Avg EPS beat(12)8.33%
EPS beat(16)9
Avg EPS beat(16)6.63%
Revenue beat(2)0
Avg Revenue beat(2)-1.81%
Min Revenue beat(2)-1.89%
Max Revenue beat(2)-1.72%
Revenue beat(4)0
Avg Revenue beat(4)-1.47%
Min Revenue beat(4)-1.89%
Max Revenue beat(4)-0.98%
Revenue beat(8)0
Avg Revenue beat(8)-2.01%
Revenue beat(12)3
Avg Revenue beat(12)-1.95%
Revenue beat(16)6
Avg Revenue beat(16)0.31%
PT rev (1m)-45.8%
PT rev (3m)-52.03%
EPS NQ rev (1m)-14.83%
EPS NQ rev (3m)-8.11%
EPS NY rev (1m)0%
EPS NY rev (3m)20.44%
Revenue NQ rev (1m)-6.28%
Revenue NQ rev (3m)-6.48%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)-0.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.05
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.53
EPS(TTM)-1.11
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS1.68
BVpS-3.78
TBVpS-3.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -269.22%
ROE N/A
ROCE 483.52%
ROIC 381.98%
ROICexc 1178.47%
ROICexgc 1178.47%
OM 378.2%
PM (TTM) N/A
GM 27.14%
FCFM N/A
ROA(3y)-61.41%
ROA(5y)-52.18%
ROE(3y)-1031.52%
ROE(5y)-647.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.59%
GM growth 5Y-3.73%
F-Score3
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.68
Cap/Depr 6.96%
Cap/Sales 1.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 2.25
Altman-Z -3.51
F-Score3
WACC2.22%
ROIC/WACC172.06
Cap/Depr(3y)54.7%
Cap/Depr(5y)66.37%
Cap/Sales(3y)10.13%
Cap/Sales(5y)8.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.19%
EPS Next Y53.25%
EPS Next 2Y26.21%
EPS Next 3Y18.34%
EPS Next 5Y12.71%
Revenue 1Y (TTM)-7.37%
Revenue growth 3Y33.54%
Revenue growth 5Y49.91%
Sales Q2Q%-9.21%
Revenue Next Year-6.03%
Revenue Next 2Y0.81%
Revenue Next 3Y3.75%
Revenue Next 5Y3.73%
EBIT growth 1Y329.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.63%
EBIT Next 3Y20.35%
EBIT Next 5Y16.33%
FCF growth 1Y54.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.11%
OCF growth 3YN/A
OCF growth 5YN/A